Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome
2010

Plasma Neuropeptide Y as a Biomarker for Chronic Fatigue Syndrome

Sample size: 193 publication Evidence: moderate

Author Information

Author(s): Mary A. Fletcher, Martin Rosenthal, Michael Antoni, Gail Ironson, Xiao R. Zeng, Zachary Barnes, Jeanna M. Harvey, Barry Hurwitz, Silvina Levis, Gordon Broderick, Nancy G. Klimas

Primary Institution: University of Miami

Hypothesis

Neuropeptide Y (NPY) would be a useful biomarker for chronic fatigue syndrome (CFS).

Conclusion

Plasma NPY is elevated in CFS patients compared to healthy controls and is associated with stress and negative mood.

Supporting Evidence

  • CFS patients had significantly higher plasma NPY levels compared to healthy controls.
  • NPY levels correlated with perceived stress, depression, and cognitive status in CFS patients.
  • The study included a comparison group of patients with Gulf War Illness.

Takeaway

This study found that a substance called neuropeptide Y is higher in people with chronic fatigue syndrome, which might help doctors understand and treat the illness better.

Methodology

The study measured plasma NPY levels in CFS patients and compared them to healthy controls and patients with Gulf War Illness, using various psychometric measures.

Limitations

The study represents a single point in time and does not account for the variability of biomarkers over time.

Participant Demographics

CFS patients (n=93, 83% female, mean age 44), healthy controls (n=100, 84% female, mean age 41), and Gulf War Illness patients (n=37, 29% female, mean age 44).

Statistical Information

P-Value

p = .000

Confidence Interval

95% CI: 0.577 to 0.733 for CFS vs controls; 95% CI: 0.561 to 0.771 for CFS vs GWI

Statistical Significance

p < 0.05

Digital Object Identifier (DOI)

10.1186/1744-9081-6-76

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication